Turning Point Therapeutics, Inc. Common Stock
TPTX
TPTX was delisted on the 16th of August, 2022.
202 hedge funds and large institutions have $4.21B invested in Turning Point Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 70 increasing their positions, 80 reducing their positions, and 21 closing their positions.
141% more call options, than puts
Call options by funds: $7.61M | Put options by funds: $3.16M
52% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 21
5% more funds holding
Funds holding: 193 → 202 (+9)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
13% less repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 80
20% less capital invested
Capital invested by funds: $5.28B → $4.21B (-$1.07B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$59.5M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$53.6M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$47M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$42.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$30M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$45.7M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$25.5M |
| 3 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$21M |
| 4 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$17.9M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$15.7M |
TPTX Hedge Fund Activity: Q1 2021 in Review
202 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Turning Point Therapeutics, Inc. Common Stock (TPTX) for Q1 2021, worth a combined $4.21B — down 20% from $5.28B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new TPTX positions and 21 closed out — a net gain of 11 holders — while 70 added to existing stakes and 80 trimmed.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $59.5M. The largest seller was OrbiMed, cutting an estimated $45.7M.
- 202 institutional investors held Turning Point Therapeutics, Inc. Common Stock (TPTX) as of Q1 2021, up from 193 in Q4 2020.
- Funds reported $4.21B of Turning Point Therapeutics, Inc. Common Stock stock for Q1 2021, down 20% quarter-over-quarter.
- 32 funds opened new Turning Point Therapeutics, Inc. Common Stock positions in Q1 2021 and 21 closed out, a net change of +11 holders.
- The largest Turning Point Therapeutics, Inc. Common Stock buyer in Q1 2021 was Farallon Capital Management, an estimated $59.5M added.
- The largest Turning Point Therapeutics, Inc. Common Stock seller in Q1 2021 was OrbiMed, an estimated $45.7M sold.
Based on aggregated 13F filings for Q1 2021.